Difference between revisions of "Template:Did you know nominations/Azeloprazole"
Jump to navigation
Jump to search
imported>Biochemistry&Love (DYK nom.) |
imported>Biochemistry&Love (Wikilinked) |
||
| Line 13: | Line 13: | ||
--> | --> | ||
| − | * ... that '''azeloprazole''' was designed with [[pharmacogenomics]] in mind? <small>Source: "Azeloprazole sodium was synthesized to overcome | + | * ... that '''[[azeloprazole]]''' was designed with [[pharmacogenomics]] in mind? <small>Source: "Azeloprazole sodium was synthesized to overcome |
issues associated with the metabolism of marketed PPIs by CYP2C19." (Toda R. et al. ''The Journal of Clinical Pharmacology''. 2017;00(0):1–9. DOI:10.1002/jcph.1038.)</small> | issues associated with the metabolism of marketed PPIs by CYP2C19." (Toda R. et al. ''The Journal of Clinical Pharmacology''. 2017;00(0):1–9. DOI:10.1002/jcph.1038.)</small> | ||
:* | :* | ||
Revision as of 06:07, 26 December 2017
| DYK toolbox |
|---|
Azeloprazole
A three-dimensional representation of zeloprazole spinning along an axis.
A three-dimensional representation of zeloprazole spinning along an axis.
- ... that azeloprazole was designed with pharmacogenomics in mind? Source: "Azeloprazole sodium was synthesized to overcome
issues associated with the metabolism of marketed PPIs by CYP2C19." (Toda R. et al. The Journal of Clinical Pharmacology. 2017;00(0):1–9. DOI:10.1002/jcph.1038.)
- Comment: Moved from sandbox. About 1900 characters. Using DYK credit from Dominique Blake.
Created by Biochemistry&Love (talk). Self-nominated at 06:02, 26 December 2017 (UTC).